source
- UniQure plans to file Huntington’s disease gene therapy with FDA after leadership shift eases data requirementsUniQure, a Dutch biotech, announced it will seek FDA approval for its gene therapy targeting Huntington’s disease later this summer. The company said FDA staff indicated that three years of data f…
- Jazz partners with AbCellera on $4 billion deal to develop next-generation T-cell engagers for solid tumorsJazz Pharmaceuticals disclosed a collaboration with AbCellera aimed at creating next-generation T-cell-engaging antibodies for solid tumors. Under the agreement Jazz will pay $56 million up front…